Market will grow 18 percent for the next two years, new study suggests. Low production costs will give India an edge over other countries, particularly China and Israel, in the case of generic drugs. Study says drugs worth $40 billion in the U.S. and $25 billion in Europe will go off patent by 2007-08.
Source: hindu.com
Source: hindu.com